

Econ Healthcare (Asia) Limited and its subsidiaries Registration Number: 200400965N

Condensed consolidated financial statements For the six months and full year ended 31 March 2022

The Company has prepared this announcement and its contents have been reviewed by DBS Bank Ltd ('Sponsor') for compliance with the Catalist Rules. The Sponsor has not independently verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact persons of the Sponsor are Mr Goh Chyan Pit, Managing Director and Mr Kelvin Wong, Senior Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone +65 6878 8888.

Table of contents	Page
Condensed consolidated income statement	2
Condensed consolidated statement of comprehensive income	3
Condensed consolidated statements of financial position	4
Condensed consolidated statements of changes in equity	5
Condensed consolidated statement of cash flows	8
Notes to the condensed consolidated financial statements	10
Other information required by Listing Rule Appendix 7.2	29

Certain numerical figures set out in this Announcement, including financial data presented in millions or thousands and percentages, have been subject to rounding adjustments, and, as a result, the totals of the data in this Announcement may vary slightly from the actual arithmetic totals of such information. Percentages and amounts reflecting changes over time periods relating to financial and other data set forth in paragraph 4 of other information required by Listing Rule 7.2 of this Announcement are approximate figures and have been calculated using the numerical data in our consolidated financial statements or the tabular presentation of other data (subject to rounding) contained in this Announcement, as applicable, and not using the numerical data in the narrative description thereof.

Condensed consolidated income statement For the six months and full year ended 31 March 2022

		Six montl 31 M			Full year 31 Ma		
	Note	2022 \$'000	2021 \$'000	Change %	2022 \$'000	2021 \$'000	Change %
Revenue	5	19,325	19,082	1.3	38,905	37,660	3.3
Other income	6	4,240	3,293	28.8	5,208	6,468	(19.5)
Supplies and consumables		(2,946)	(2,836)	3.9	(5,849)	(5,462)	7.1
Staff costs Depreciation of property, plan	ıt	(9,686)	(9,249)	4.7	(19,357)	(18,469)	4.8
and equipment Depreciation of right-of-use		(748)	(602)	24.3	(1,379)	(1,123)	22.8
assets		(3,377)	(2,601)	29.8	(6,014)	(5,174)	16.2
Utilities expenses Impairment losses on trade		(560)	(454)	23.3	(1,051)	(948)	10.9
receivables Loss on investment in quoted		(99)	(4)	2375.0	(101)	(14)	621.4
securities, net		(3,354)	_	N.M.	(3,354)	_	N.M.
Other operating expenses	-	(2,779)	(3,391)	(18.0)	(4,657)	(4,763)	(2.2)
		16	3,238	(99.5)	2,351	8,175	(71.2)
Finance costs, net Share of result of associate an	7 d	(875)	(635)	37.8	(1,460)	(1,353)	7.9
joint venture, net of tax		(30)	_	N.M.	(30)	5	(700.0)
(Loss)/profit before tax	_	(889)	2,603	(134.2)	861	6,827	(87.4)
Tax expense	9	(588)	(769)	(23.5)	(917)	(1,456)	(37.0)
(Loss)/profit for the period/year	8	(1,477)	1,834	(180.5)	(56)	5,371	(101.0)
(Loss)/profit attributable to:	:						
Owner of the Company		(1,262)	2,048	(161.6)	350	5,700	(93.9)
Non-controlling interests		(215)	(214)	0.5	(406)	(329)	23.4
(Loss)/profit for the period/year	-	(1,477)	1,834	(180.5)	(56)	5,371	(101.0)
Earnings per share Basic and diluted earnings per				_ =			-
share (cents)	17	(0.49)	0.99	(149.6)	0.14	2.75	(95.1)

N.M. – Not meaningful

Condensed consolidated income statement

For the six months and full year ended 31 March 2022	
	_

	Six month 31 Ma			Full year 31 Mai		
	2022 \$'000	2021 \$'000	Change %	2022 \$'000	2021 \$'000	Change %
(Loss)/profit for the period/year	(1,477)	1,834	(180.5)	(56)	5,371	(101.0)
Other comprehensive income Items that are or may be reclassified subsequently to profit or loss:						
Foreign currency translation differences – foreign operations	(101)	(183)	(44.8)	(51)	(212)	(75.9)
Total comprehensive (loss)/income for the						-
period/year	(1,578)	1,651	(195.6)	(107)	5,159	(102.1)
Total comprehensive income attributable to:						
Owner of the Company	(1,374)	1,831	(175.0)	267	5,447	(95.3)
Non-controlling interests	(204)	(180)	13.3	(374)	(288)	29.9
Total comprehensive (loss)/income for the		· · · · ·				-
period/year	(1,578)	1,651	(195.6)	(107)	5,159	(102.1)

N.M. – Not meaningful

		Gro		Company			
	Note	31 March 2022 \$'000	31 March 2021 \$'000	31 March 2022 \$'000	31 March 2021 \$'000		
Assets		4 000	\$ 000	4 000	4 000		
Property, plant and							
equipment	10	17,930	16,476	814	938		
Right-of-use assets	11	40,858	27,154	3,791	5,454		
Investment property	12	8,092	8,154	_	_		
Joint venture		—	_	—	-		
Trade and other receivables	13	1,757	1,128	1,912	1,581		
Deferred tax assets		133	31	5	3		
Finance lease receivables		—	18	-	-		
Subsidiaries		-	_	23,899	23,922		
Associate	-	53	-	-	- 21.000		
Non-current assets	_	68,823	52,961	30,421	31,898		
Trade and other receivables	13	5,552	3,352	2,738	700		
Cash and cash equivalents		26,102	16,095	13,283	5,097		
Inventories		13	14	_	_		
Finance lease receivables		18	36	—	-		
Current tax assets	_	230	196	-	_		
Current assets	_	31,915	19,693	16,021	5,797		
Total assets	=	100,738	72,654	46,442	37,695		
Equity							
Share capital	14	28,255	15,000	28,255	15,000		
Currency translation reserve	15	(2,923)	(2,841)	,	, _		
Merger reserve	15	(99)	(99)	-	—		
Accumulated profits		10,436	12,656	9,891	6,851		
Equity attributable to							
owner of the Company		35,669	24,716	38,146	21,851		
Non-controlling interests	_	273	514	_	-		
Total equity	_	35,942	25,230	38,146	21,851		
Liabilities							
Loans and borrowings	18	3,147	4,536	_	_		
Deferred tax liabilities		357	364	_	_		
Deferred capital grants		1,606	277	_	_		
Provision for restoration							
costs		632	504	217	215		
Lease liabilities	_	35,748	23,677	2,247	3,973		
Non-current liabilities	_	41,490	29,358	2,464	4,188		
Loans and borrowings	18	3,997	5,825	_	_		
Trade and other payables	19	11,250	5,978	4,046	9,910		
Lease liabilities		7,083	5,084	1,725	1,666		
Current tax liabilities		976	1,179	61	80		
Current liabilities	—	23,306	18,066	5,832	11,656		
Total liabilities	—	64,796	47,424	8,296	15,844		
Total equity and liabilities	-	100,738	72,654	46,442	37,695		
1	-	,		,	2.,270		

Condensed consolidated statements of financial position As at 31 March 2022

Condensed consolidated statement of changes in equity For the full year ended 31 March 2022

Group	Share capital \$'000	Currency translation reserve \$'000	Merger reserve \$'000	Accumulated profits \$'000	Total equity attributable to owner of the Company \$'000	Non-controlling interests \$'000	Total equity \$'000
At 1 April 2021	15,000	(2,841)	(99)	12,656	24,716	514	25,230
Total comprehensive income for the year Profit/(loss) for the year Other comprehensive income	_	_	_	350	350	(406)	(56)
Foreign currency translation differences – foreign operations	_	(82)	_	_	(82)	31	(51)
Total comprehensive income for the year		(82)	_	350	268	(375)	(107)
Transactions with owner, recognised directly in equity							
Dividends paid	_	_	_	(2,570)	(2,570)	_	(2,570)
Shares issued	14,000	_	_	_	14,000	_	14,000
Offset of listing expenses	(745)	_	_	_	(745)	-	(745)
Capital contribution by non- controlling interests		_	_	_	_	134	134
Total contributions by and distribution to owner	13,255	_	_	(2,570)	10,685	134	10,819
At 31 March 2022	28,255	(2,923)	(99)	10,436	35,669	273	35,942

Condensed consolidated statement of changes in equity For the full year ended 31 March 2022

Group	Share capital \$'000	Currency translation reserve \$'000	Merger reserve \$'000	Accumulated profits \$'000	Total equity attributable to owner of the Company \$'000	Non-controlling interests \$'000	Total equity \$'000
At 1 April 2020	15,000	(2,588)	(99)	6,956	19,269	(131)	19,138
Total comprehensive income for the year							
Profit/(loss) for the year	-	-	-	5,700	5,700	(329)	5,371
Other comprehensive income							
Foreign currency translation					(
differences – foreign operations	-	(253)	_	_	(253)	41	(212)
Total comprehensive income for the year		(253)	_	5,700	5,447	(288)	5,159
Transactions with owner, recognised directly in equity							
Capital contribution by non- controlling interests		_	_	_	_	933	933
At 31 March 2021	15,000	(2,841)	(99)	12,656	24,716	514	25,230

Condensed statements of changes in equity For the full year ended 31 March 2022

Company	Share capital \$'000	Retained earnings \$'000	Total equity \$'000
At 1 April 2021	15,000	6,851	21,851
Total comprehensive income for the year Profit for the year Total comprehensive income for the year		5,610 5,610	5,610 5,610
Transactions with owner, recognised directly in equity			
Dividends paid	_	(2,570)	(2,570)
Share issued	14,000	_	14,000
Offset of listing expenses	(745)	_	(745)
Total transactions with owners	13,255	(2,570)	10,685
At 31 March 2022	28,255	9,891	38,146
At 1 April 2020	15,000	7,251	22,251
Total comprehensive income for the year			
Loss for the year		(400)	(400)
Total comprehensive income for the year		(400)	(400)
At 31 March 2021	15,000	6,851	21,851

Condensed consolidated statement of cash flows For the full year ended 31 March 2022

	2022 \$'000	2021 \$'000
Cash flows from operating activities		
Profit before tax	861	6,827
Adjustments for:		
Amortisation of deferred capital grant	(178)	(42)
Write-off of property, plant and equipment	364	32
Depreciation of property, plant and equipment	1,379	1,123
Depreciation of right-of-use assets	6,014	5,174
Re-measurement from lease modification	(7()	38
(Gain)/loss on termination of leases	(76)	11
Impairment losses on trade receivables	101	14 62
Impairment losses on property, plant and equipment Interest income	(3)	(19)
Interest income	1,430	1,350
Rent concessions	(659)	(501)
Unwinding of discount on provisions	3	3
Reversal of provision for restoration cost	_	(7)
Loss on disposal of joint venture	_	5
Share of profit of joint venture, net of tax	_	(5)
Share of loss of associate, net of tax	30	_
Dividends income from investment in quoted securities	(8)	_
Loss on investment in quoted securities, net	3,354	_
	12,612	14,065
Changes in:		
- Trade and other receivables	(3,467)	1,795
- Trade and other payables	4,677	674
- Inventories	*	(6)
Cash generated from operations	13,822	16,528
Tax paid	(1,264)	(914)
Net cash from operating activities	12,558	15,614
Cash flows from investing activities		
Change in non-trade amounts due from immediate holding		((00))
company Change in non-trade amounts due forme e related company	_	(698)
Change in non-trade amounts due from a related company Finance lease received	37	488 37
Interest received		1.5
Proceeds from disposal of plant and equipment	2 9	17
Proceeds from disposal of joint venture	, _	_*
Investment in associate	(83)	_
Purchase of property, plant and equipment	(2,630)	(2,441)
Placement of fixed deposits with licensed banks	_*	(2,111)
Restricted cash held with bank	_	(31)
Capital grants received	1,505	73
Dividends income from investment in quoted securities	8	_
Investment in quoted securities	(5,104)	_
Proceeds from disposal of quoted securities	1,750	_
Net cash used in investing activities	(4,506)	(2,557)
5		

* Less than \$1,000

Condensed consolidated statement of cash flows (cont'd) For the full year ended 31 March 2022

	2022 \$'000	2021 \$'000
Cash flows from financing activities		
Capital contribution by non-controlling interests	134	933
Proceeds from borrowings	130	2,360
Repayment of borrowings	(3,306)	(1,554)
Payment of lease liabilities	(4,881)	(4,463)
Interest paid	(1,121)	(1,286)
Dividends paid	(2,570)	_
Proceeds from issuance of shares pursuant to initial public		
offering	14,000	_
Payment of initial public offering transaction costs	(408)	(337)
Net cash from/(used in) financing activities	1,978	(4,347)
Net increase in cash and cash equivalents	10.030	8,710
Cash and cash equivalents at 1 April	16,029	7,301
Effect of exchange rate fluctuations on cash held	(24)	18
Cash and cash equivalents at 31 March	26,035	16,029

For the purpose of the consolidated cash flow statement, cash and cash equivalents comprise the following at the end of the reporting period:

	2022 \$'000	2021 \$'000
Cash at bank and fixed deposits	26,102	16,095
Less: Fixed deposits with maturity more than 90 days at		
period end	(35)	(35)
Less: Restricted fixed deposit	(32)	(31)
Cash and cash equivalents in consolidated statement of cash		
flows	26,035	16,029

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

1 Corporate information

The Company was incorporated on 28 January 2004 under the name of EHL (S) Pte. Ltd and is domiciled in Singapore. On 16 February 2006, the Company changed its name to Econ Healthcare (S) Pte. Ltd. On 29 March 2021, the Company was converted into a public company limited by shares and changed its name to Econ Healthcare (Asia) Limited. The Company was listed on the Catalist Board of Singapore Exchange Securities Trading Limited ("SGX-ST") on 19 April 2021. The Company's registered address and principal place of business is at 160 Changi Road, #05-01-13 Hexacube, Singapore 419728.

These condensed consolidated financial statements of the Group as at and for the six months and full year ended 31 March 2022 comprise the Company and its subsidiaries (together referred to as the "Group" and individually as "Group entities").

The immediate and ultimate holding companies are Econ Healthcare Pte. Ltd. and Econ Investment Holdings Pte. Ltd. respectively, both of which are incorporated in Singapore.

The principal activities of the Group are those relating to the operation of medicare centres and nursing homes, provision of hospital extension ward management services, homecare services, ambulance services and investment holding.

2 Basis of preparation

The condensed consolidated financial statements for the six months and full year ended 31 March 2022 have been prepared in accordance with Singapore Financial Reporting Standards (International) ("SFRS(I)") 1-34 *Interim Financial Reporting* by the Accounting Standards Council Singapore. The condensed consolidated financial statements do not include all of the information required for a complete set of financial statements. However, selected explanatory notes are included to explain the events and transactions that are significant to understanding of the changes in the Group's financial position and performance since the last interim financial statements for the period ended 30 September 2021.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed consolidated financial statements are presented in Singapore dollar ("\$") and all values are rounded to the nearest thousand ("\$'000"), except when otherwise indicated.

2.1 New and amended standards adopted by the Group

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except in the current financial year, the Company has adopted all the new and revised standards which are effective for annual financial periods beginning on or after 1 April 2021. The adoption of these standards did not have any material effect on the financial performance or position of the Group.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

2.2 Use of judgements and estimates

In preparing the condensed consolidated financial statements, management has made judgements, estimates and assumptions that affect the application of the Group's accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 March 2021.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

3 Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the period under review.

4 Segment information

The Group has two (2) reportable segments, as described below, which are the Group's strategic business units. The strategic businesses are managed separately because they require different operation needs and marketing strategies. For each operating segment, the Group's Chief Executive Officer (the chief operating decision maker) reviews the internal management reports on a monthly basis.

For the purpose of financial reporting, the following summary describes the operations in each of the Group's reportable segments:

•	Medicare centres and nursing homes	:	Include provision of residential nursing care services, home care services, physiotherapy and rehabilitation services, clinical services and TCM treatments in medicare centres and nursing homes.
•	Other operation and ancillary services	:	Include provision of management services, ambulance services, healthcare training services, the offering of TCM services at our TCM clinics and the operation of senior activity centres in Singapore.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

Information about reportable segments

	Medicare centres and nursing homes \$'000	Other operation and ancillary services \$'000	Eliminations \$'000	Total \$'000
Six months ended 31 March 2022				
Revenue				
External revenue	18,929	396	-	19,325
Inter-segment revenue	18,929	3,998 4,394	(3,998) (3,998)	19,325
Results:				
Segment results	2,728	674	(13)	3,389
Finance income	_,0	_	()	1
Finance costs	(981)	(52)	157	(876)
Share of results of associate	_	(30)	_	(30)
Unallocated expenses: Listing expenses	_	_	_	(19)
Unallocated expenses: Loss on				(1))
investment in quoted securities	_	_	_	(3,354)
Segment profit/(loss) before tax	1,748	592	144	(889)
Significant non-cash items Depreciation of property, plant and equipment Depreciation of right-of-use assets Impairment losses on trade	652 2,465	96 912		748 3,377
receivables	99	_	_	99
Six months ended 31 March 2021 Revenue External revenue Inter-segment revenue	18,652 	430 4,729 5,159	(4,729) (4,729)	19,082 19,082
Results:				
Segment results	3,362	1,340	183	4,885
Finance income	8	1	_	9
Finance costs	(952)	(72)	380	(644)
Unallocated expenses: Listing expenses	_	_	_	(1,647)
Segment profit before tax	2,418	1,269	563	2,603
Significant non-cash items Depreciation of property, plant and equipment Depreciation of right-of-use assets	474 1,712	128 889		602 2,601
(Reversal) of impairment losses on trade receivables	(94)		98	4

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

	Medicare centres and nursing homes \$'000	Other operation and ancillary services \$'000	Eliminations \$'000	Total \$'000
Full year ended 31 March 2022				
Revenue External revenue	38,092	813		38,905
Inter-segment revenue		8,208	(8,208)	- 58,905
	38,092	9,021	(8,208)	38,905
Results:				
Segment results	5,032	705	(13)	5,724
Finance income	2	1	(15)	3,721
Finance costs	(1,507)	(113)	157	(1,463)
Share of results of associate	_	(30)	_	(30)
Unallocated expenses: Listing				
expenses	_	_	_	(19)
Unallocated expenses: Loss on				(2, 254)
investment in quoted securities Segment profit before tax	3,515	563		(3,354) 861
Segment pront before tax		505	144	001
Significant non-cash items				
Depreciation of property, plant and				
equipment	1,195	184	_	1,379
Depreciation of right-of-use assets	4,209	1,805	_	6,014
Impairment losses on trade	101			101
receivables	101	_	_	101
Full year ended 31 March 2021				
Revenue				
External revenue	36,588	1,072	_	37,660
Inter-segment revenue		7,322	(7,322)	-
	36,588	8,394	(7,322)	37,660
Results:				
Segment results	7,677	1,962	183	9,822
Finance income	17	2	-	19
Finance costs	(1,583)	(169)	380	(1,372)
Share of results of joint venture	_	5	_	5
Unallocated expenses: Listing				
expenses		_	_	(1,647)
Segment profit before tax	6,111	1,800	563	6,827
Significant non-cash items Depreciation of property, plant and				
equipment	885	238	_	1,123
Depreciation of right-of-use assets	3,404	1,770	_	5,174
(Reversal) of impairment losses on	(0.4)		0.0	1 4
trade receivables	(84)		98	14

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

	Medicare centres and nursing homes \$'000	Other operation and ancillary services \$'000	Eliminations \$'000	Total \$'000
As at 31 March 2022				
Assets:				
Investment in associate	-	53	_	53
Segment assets	85,624	69,665	(54,967)	100,310
Tax assets	354	9	_	363
Total assets	85,978	69,727	(54,967)	100,738
Liabilities:				
Segment liabilities	81,556	36,399	(54,492)	63,463
Tax liabilities	1,272	61	(- , , , , _)	1,331
Total liabilities	82,828	36,460	(54,492)	64,796
Capital expenditure	3,177	48	_	3,225
As at 31 March 2021				
Assets:	69,540	58,354	(55,804)	72,090
Segment assets Tax assets	69,340 179	38,334 48	(33,804)	227
Unallocated assets: Prepaid listing	175	40	—	221
expenses	_	_	_	337
Total assets	69,719	58,403	(55,804)	72,654
Liabilities:				
Segment liabilities	60,662	41,980	(57,579)	45,063
Tax liabilities	1,463	80	_	1,543
Unallocated liabilities: Accrued	_,			-,
listing expenses	_	_	—	817
Total liabilities	62,126	42,060	(57,579)	47,423
Capital expenditure	2,646	107	_	2,753

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

Geographical information

External customers of the Group are located in Singapore, Malaysia and China. The Group carries out its operations in Singapore, Malaysia and China and all the Group's non-current assets are located in Singapore, Malaysia and China.

In presenting the information on the basis of geographical segments, segmental revenue is based on the geographical location of the customers and segmental assets are based on the geographical location of the assets.

	Six months ended 31 March		Full year ended 31 March	
	2022	2021	2022 \$'000	2021 \$'000
Revenue				
Singapore	16,875	16,527	33,771	32,523
Malaysia	2,246	2,555	4,768	5,137
China	204	_	366	_
Consolidated revenue	19,325	19,082	38,905	37,660

	31 March 2022 \$'000	31 March 2021 \$'000
Non-current assets ⁽¹⁾		
Singapore	36,316	26,778
Malaysia	22,301	23,919
China	10,073	2,234
Consolidated total non-current assets	68,690	52,931

⁽¹⁾ Non-current assets information presented above consist of property, plant and equipment, right-of-use assets, investment property, non-current trade and other receivables, non-current finance lease receivables and investment in associate.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

Revenue

5

	Medicare c	entres and nur fees	rsing homes	•	——— Ancilla	nry fees ——		
Six months ended 31 March	Home fees \$'000	Home care and day care and other nursing home services \$'000	Operating subvention grant	Course fees \$'000	Management fee \$'000	Traditional Chinese medicine ("TCM") clinics services \$'000	Other ancillary services \$'000	Total \$'000
2022								
Third parties - Singapore	5 242	1 777	0.450	26		358	_*	16,863
- Singapore - Malaysia	5,243 1,600	1,777 646	9,459	26	_	338	_*	2,246
- China	37	167	_	_	_	_	_	2,240
- China	6,880	2,590	9,459	26	_	358	_*	19,301
Affiliated corporation	0,880	2,390	9,439	20	_	338	_	19,501
 Singapore 	_	-	-	-	12	-	-	12
	6,880	2,590	9,459	26	12	358	_*	19,325
2021 Third parties	4.025	2 224	0.020	2		414	ň	16 510
- Singapore	4,935	2,224	8,938	2	_	414	_*	16,513
- Malaysia	1,887	668	-	-	_		*	2,555
Related corporation - Singapore	6,822	2,892	8,938	2	_	414	_* _	19,068 -
Affiliated corporation								
 Singapore 	_	-	-	_	14	-	-	14
	6,822	2,892	8,938	2	14	414	_*	19,082
Full year ended 31 March 2022 Third parties								
- Singapore	10,880	3,435	18,643	28	_	762	_*	33,748
- Malaysia	3,304	1,464	_	_	_	_	_	4,768
- China	65	301	-	_	-	_	-	366
	14,249	5,200	18,643	28	-	762	_*	38,882
Affiliated corporation								
- Singapore	_	_	_	_	23	_	_	23
	14,249	5,200	18,643	28	23	762	_*	38,905

* Less than \$1,000

	Medicare c	entres and nu fees	rsing homes	•	Ancilla	ary fees ——		
Full year ended 31 March	Home fees \$'000	Home care and day care and other nursing home services \$'000	Operating subvention grant	Course fees \$'000	Management fee \$'000	Traditional Chinese medicine ("TCM") clinics services \$'000	Other ancillary services \$'000	Total \$'000
2021 Third parties								
Third parties - Singapore	10,570	3,600	17,282	2	_	729	_*	32,183
- Malaysia	3,730	1,407		_	_	-	_	5,137
2	14,299	5,007	17,282	2	_	729	_*	37,320
Related corporation - Singapore	_	_	_	1	315	_	_	316
Affiliated corporation								
- Singapore		_		-	24	_	-	24
	14,299	5,007	17,282	3	339	729	_*	37,660

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

Home fees generally relate to contracts with patients in which performance obligations are to provide nursing home healthcare services to individual patients in Singapore, Malaysia and China. Home care and day care fees generally relate to contracts with patients in which performance obligations are to provide healthcare services to individual patients at their homes. Ambulance fees relate to provision of medical and passenger transport services to individual patients and related corporations in Singapore. Course fees relate to contracts with corporate customers in which performance obligations are to provide training for nurses, nursing home managers and home caregivers in Singapore. Management fee relates to provision of management and consultancy services to a related corporation. Traditional Chinese Medicine ("TCM") clinic services relate to the offering of TCM services at TCM clinics.

Other nursing home services relate to provision of dressing, rehabilitation services, TCM treatments and other medical related services to individual patients.

The performance obligations for nursing home healthcare services, home care services, management services and training services are generally satisfied over time and revenue is recorded when the services are performed. The performance obligations for medical and passenger transport services and other ancillary services are generally satisfied at a point in time.

Invoices are issued based on contractual terms. The Group has a credit term of 10 to 30 days which is typically short term, in line with market practice, without any financing component. There are no variable considerations, and no obligations for returns or refunds or warranties for healthcare-related services.

Operating subvention grants were provided by the government to the Group for the purposes of providing subsidised nursing home care services during the approved period. The scheme allows the Group to set aside a portion of its beds for eligible patients who meet the means test criteria to enjoy the subsidies. These patients are generally older persons who are unable to receive adequate level of nursing care in their own homes, require assistance with their daily activities as well as persons who need further care and treatment after being discharged from an acute hospital.

Operating subvention grants are recognised in the profit or loss when conditions attached to its recognition are met by the Group.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

6 Other income

March March	Full year ended 31 March	
2022 2021 2022 \$'000 \$'000 \$'000	2021 \$'000	
Other government grants:		
- Grants on special employment		
credit, temporary employment		
credit and wages credit scheme 90 57 107	99	
- Grant on Senior Activity Centres – – –	180	
- Grants on Jobs Support Scheme – 471 128	1,277	
- Foreign worker levy rebate – 159 –	651	
- Grants on staff accommodation 158 1,081 218	1,832	
- S Pass and work permit levy		
transition support 160 241 160	241	
- Employment grant 24 239 24	239	
- Grants on Senior Management		
Associate Scheme 152 91 152	91	
- Grants on Scale-up SG		
Programme – 70 –	70	
- Grants on Jobs Growth Incentive 233 11 370	11	
- Eldercare centre baseline service		
transition grants 420 – 420	_	
- Grant for Equity Market		
Singapore 200 – 200	—	
- Work-life Grants 70 – 70	_	
- Grants on community care salary		
enhancements 384 – 384	_	
- Grants on Healthcare Hiring In		
Advance Initiatives 312 – 312	—	
Rent concessions527-659	501	
Rental income135120259	224	
Amortisation of deferred capital		
grants 99 31 178	42	
Service fees 53 53 106	106	
Property tax rebate – 13 –	54	
Recovery of shareholder loans – 375 –	375	
Dividends income from quoted		
securities 8 – 8	—	
Gain on lease termination76-76	—	
Rental subsidy/subvention grants830187986	249	
Pre-operations funding 176 – 176	—	
Others <u>133</u> 94 215	226	
4,240 3,293 5,208	6,468	

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

Finance costs, net

7

	Six months ender 2022 \$'000	ed 31 March 2021 \$'000	Full year ende 2022 \$'000	d 31 March 2021 \$'000
Interest income from bank deposits Interest income from finance	1	8	2	17
lease receivables	_	1	1	2
Finance income	1	9	3	19
Exchange loss, net Interest expense on bank borrowings Unwinding of discount on	(16) (135)	(11) (151)	(30) (263)	(19) (362)
provision of restoration cost Interest expense from lease	(2)	(1)	(3)	(3)
liabilities	(723)	(481)	(1,167)	(988)
Finance costs	(876)	(644)	(1,463)	(1,372)
Net finance costs	(875)	(635)	(1,460)	(1,353)

8 (Loss)/profit for the period/year

The following items have been included in arriving at (loss)/profit for the period/year:

	Six months end 2022 \$'000	ed 31 March 2021 \$'000	Full year ende 2022 \$'000	ed 31 March 2021 \$'000
Initial public offering expenses	(19)	1,647	61	1,647
Write-off of property, plant and				
equipment	346	32	364	32
Expenses relating to short-term				
leases presented in "staff				
costs"	112	224	254	225
Repair and maintenance				
expenses	903	425	1,449	800
Contributions to defined				
contribution plans				
included in				
staff costs	584	505	1,048	913
Directors' fees	43	29	85	56

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

9 Income tax expense

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense for the six months and full year ended 31 March 2022 and 2021 are:

	Six months ended 31 March		Full year ended 31 March	
	2022			2021
	\$'000	\$'000	\$'000	\$'000
Current tax expense	637	700	1,023	1,423
Deferred tax (credit)/expense	(49)	69	(106)	33
	588	769	917	1,456

10 Property, plant and equipment

During the year ended 31 March 2022, the Group acquired property, plant and equipment of \$3,225,000 (31 March 2021: \$2,753,000).

As at 31 March 2022, the Group has made commitments for capital expenditure of \$3,297,000 (31 March 2021: \$991,000).

11 Right-of-use assets

During the year ended 31 March 2022, the Group recognised additions of right-of-use assets of \$20,015,000 (31 March 2021: \$397,000).

12 Investment property

	31 March 2022 \$'000	31 March 2021 \$'000
At beginning of the year, at cost	8,154	8,281
Translation differences on consolidation	(62)	(127)
At end of the year	8,092	8,154

Investment property comprises a freehold land that is leased to a third party during the year. The lease contains an initial non-cancellable period of three years with option to renew for additional three years.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

Amounts recognised in profit or loss

	Six months end	Six months ended 31 March		d 31 March
	2022 \$'000	2021 \$'000	2022 \$'000	2021 \$'000
Rental income	116	100	221	183
Direct operating expenses	(3)	(3)	(6)	(6)

The fair value of the investment property amount to \$8,082,000 (31 March 2021: \$8,112,000).

The fair value of investment property located in Malaysia is determined by an independent valuer who has appropriate recognised professional qualifications and recent experience in the location and category of properties being valued.

The investment property is categorised under Level 2 of the fair value measurement hierarchy. The fair value of investment property is based on market value using direct comparison method. It is an estimated amount for which a property could be exchanged on the date of the valuation between a willing buyer and a willing seller in an arm's length transaction after proper marketing wherein the parties had each acted knowledgeably. Due adjustments for difference between the properties and the comparables in terms of location, tenure, size, shape, floor level, age and conditions of properties and date of transactions affecting its value were made in arriving at the fair value of investment property.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

13 Trade and other receivables

	Group		Com	Dany
	31 March 2022 \$'000	31 March 2021 \$'000	31 March 2022 \$'000	31 March 2021 \$'000
Trade receivables – third parties	1,590	1,668	_	_
Less: Impairment losses	(324)	(228)	_	_
-	1,266	1,440	-	
Trade amounts due from:				
- subsidiaries	_	_	2,118	1,245
Impairment losses	_	_	(356)	(356)
Total trade receivables	1,266	1,440	1,762	889
Government grant receivables for				
operating subvention grants	1,206	817	_	_
Other government grant				
receivables	1,368	166	-	-
Other receivables	983	90	204	20
Staff advances	15	25	135	-
Deposits	2,004	1,302	766	763
Non-trade amounts due from:				
- subsidiaries	_	_	1,963	465
Impairment losses	_	_	(309)	(341)
Financial assets at amortised cost	6,842	3,840	4,521	1,796
Prepayments	467	183	129	97
Prepaid listing expenses	_	337	_	337
Government grant receivables for				
Jobs Support Scheme	_	120	_	51
-	7,309	4,480	4,650	2,281
Non-current	1,757	1,128	1,912	1,581
Current	5,552	3,352	2,738	700
-	7,309	4,480	4,650	2,281
=		1	,	,

Non-trade amounts due from a related corporation and subsidiaries are unsecured, interest-free and repayable on demand.

Non-current amounts relate mainly to security deposits paid for leased premises. The security deposits are interest-free and are refundable at lease expiry or earlier termination of the lease.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

14 Share capital

	Number of shares		Amo	unt
	31 March 2022	31 March 2021	31 March 2022 \$'000	31 March 2021 \$'000
Group and Company				
Issued and fully paid ordinary shares, at par value:				
In issue at beginning of the year	207,000,000	15,000,000	15,000	15,000
Shares arising from share split	—	192,000,000	—	_
Shares issued pursuant to initial				
public offering	50,000,000	—	13,255*	_
In issue at end of the year	257,000,000	207,000,000	28,255	15,000

* Comprise of listing expenses of \$745,000 offset against proceeds from shares issued pursuant to initial public offering of \$14,000,000.

Ordinary shares

The holders of ordinary shares are entitled to receive dividends as declared from time to time, and are entitled to one vote per share at meetings of the Company. All shares rank equally with regard to the Company's residual assets.

Share spilt

Pursuant to directors' resolutions on 23 March 2021, each ordinary share in the existing issued share capital of the Company was sub-divided into 13.8 shares ("Share Split").

Initial public offering

On 19 April 2021, the Company was listed on the Catalist Board on the Singapore Exchange Securities Trading Limited (SGX-ST) and issued 50,000,000 shares representing approximately 19.46 percent of the Company's issued shares. The Company raised gross proceeds of approximately S\$14,000,000 and its share capital increased to 257,000,000 shares.

As at 31 March 2022 and 31 March 2021, there were no treasury shares held by the Company and there were no subsidiary holdings.

15 Reserves

Currency translation reserve

The currency translation reserve comprises all foreign exchange differences arising from the translation of the financial statements of foreign operations.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

Merger reserve

Merger reserve represents reserve arising from the business combinations through common control.

Dividends

During the full year period ended 31 March 2022, the Group declared dividend in amount of \$2,005,000 (S\$0.0078 per ordinary share) for FY2021 and interim dividend in amount of \$565,000 (S\$0.0022 per ordinary share) for FY2022. The dividends were fully paid.

16 Net asset value per share

	Group		Company	
	31 March 2022	31 March 2021	31 March 2022	31 March 2021
Net asset value per ordinary				
share (in cents)	13.88	11.94	14.84	10.56

17 Earnings per share

Basic earnings per share

The calculation of basic earnings per share for the six months ended 31 March 2022, full year ended 31 March 2022, six months ended 31 March 2021 and full year ended 31 March 2021 is based on the (loss)/profit attributable to ordinary shareholders of \$(1,262,000), \$350,000, \$2,048,000, and \$5,700,000 respectively and the weighted-average number of ordinary shares outstanding during the years, as follows:

	Six months ended 31 March 2022 2021		Full year end 2022	led 31 March 2021
	No. of shares	No. of shares	No. of shares	No. of shares
Issued ordinary shares at beginning of the				
period/year	257,000,000	15,000,000	207,000,000	15,000,000
Sub-division of ordinary shares via share split Shares issued pursuant to initial	_	207,000,000	_	207,000,000
public offering		_	50,000,000	
Weighted-average number of ordinary shares at end of the period/year	257,000,000	207,000,000	257,000,000	207,000,000

Diluted earnings per share

As at 31 March 2022 and 2021, there were no outstanding dilutive potential ordinary shares.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

18 Loans and borrowings

8	30 March 2022 \$'000	31 March 2021 \$'000
Non-current liabilities Bank loans	3,147	4,536
Current liabilities Bank loans	3,997 7,144	5,825 10,361

Terms and debt repayment schedule

The terms and conditions of outstanding loans and borrowings are as follows:

	Note	Currency	Nominal v interest rate %	Year of maturity	Face value \$'000	Carrying amount \$'000
31 March 2022 Group						
Unsecured bank loans	А	SGD	SIBOR + 2% Base lending rate –	2023	1,949	1,949
Secured bank loans Unsecured revolving	В	MYR	1.25%	2027	2,907	2,907
credit	С	MYR	Cost of funds + 1.50% Base lending rate –	2022	2,254	2,254
Overdraft	В	MYR	1.25%	2022	34	34
				-	7,144	7,144
				-		
31 March 2021 Group						
Secured bank loans	Α	SGD	SIBOR + 2%	2023	3,082	3,082
Secured advance facility	А	SGD	SIBOR + 2%	2021	2,004	2,004
			Base lending rate –			
Secured bank loans	В	MYR	1.25%	2027	3,101	3,101
Secured revolving credit	С	MYR	Cost of funds + 1.50%	2021	2,174	2,174
				=	10,361	10,361

A) As at 31 March 2021, the bank loan was secured by corporate guarantee from immediate holding company, joint and several personal guarantees from the directors of the Company and subsidiaries and on the immediate holding company's freehold land and building with a carrying value of \$17,478,000 and an affiliated company's investment properties with a carrying value of \$4,208,000. Affiliated company is the company controlled by the common directors. Pursuant to a deed of release dated 24 March 2021 provided by the bank, the corporate guarantee and personal guarantees from the directors of the Company and subsidiaries have been discharged on 9 April 2021. Mortgages over aforementioned freehold land, buildings and investment properties have been discharged on 9 April 2021. As at 31 March 2022, the bank loan is unsecured, and the Company shall maintain on a consolidated basis, a Gross Debt / EBITDA ratio of not more than 3.50 times.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

- B) The bank loans were secured by corporate guarantee from the Company and immediate holding company and on the Group's freehold land and building amounting to \$9,240,000 (31 March 2021: \$9,502,000). Pursuant to deed of release dated 15 March 2021 between immediate holding company and the bank, the corporate guarantee provided by the immediate holding company has been discharged.
- C) The bank loan was secured by corporate guarantee from immediate holding company and the Company. Pursuant to a deed of release dated 4 March 2021 between immediate holding company and the bank, the corporate guarantee provided by immediate holding company has been discharged on 19 April 2021. As at 31 March 2022, the bank loan is unsecured and a subsidiary of the Group shall maintain a tangible net worth of not less than Malaysian Ringgit 40,000,000 and gearing ratio shall not exceed 0.75 times.

19 Trade and other payables

	Group		Company		
	31 March 2022 \$'000	31 March 2021 \$'000	31 March 2022 \$'000	31 March 2021 \$'000	
Trade payables					
- third parties	906	746	_	-	
- subsidiaries	_	_	_	524	
	906	746	_	524	
Non-trade amount due to					
subsidiaries	_	_	2,548	7,570	
Accrued operating expenses	3,604	1,533	941	490	
Interest payables	4	21	164	_	
Other payables	473	280	330	20	
Payables to suppliers of property,					
plant and equipment	1,238	642	_	330	
Refundable deposits	1,422	1,470	-	_	
Accrued listing expenses	_	817	_	817	
Financial liabilities at amortised					
cost	7,647	5,509	3,983	9,751	
Deferred grant income	3,309	253	-	88	
Liability for short-term accumulated compensated					
absences	147	156	63	71	
Home fees collected in advance	147	60	_	_	
=	11,250	5,978	4,046	9,910	

Non-trade amounts due to subsidiaries are unsecured, interest-free and repayable on demand.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

20 Related parties

Key management personnel compensation

Key management personnel of the Group are those persons having the authority and responsibility for planning, directing and controlling the activities of the Group. The Board of Directors and senior management team are considered as key management personnel.

	Six months ended 31 March		Full year ended 31 Marcl	
	2022 \$'000	2021 \$'000	2022 \$'000	2021 \$'000
Post-employment benefits Short term employee benefits	30	29	53	47
including director fees	603	582	1,125	960
Non-monetary benefit	20	7	26	14
	653	618	1,204	1,021

Other related party transactions

Other than disclosed elsewhere in the financial statements, transactions with related parties are as follows:

	Six months ended 31 March		Full year ended	
	2022 \$'000	2021 \$'000	2022 \$'000	2021 \$'000
Ultimate holding company Payment made on behalf	(11)	_	(11)	
Immediate holding company Payment made on behalf				(3)
Related corporation				
Pharmacy expenses	-	_*	_	37
Other ancillary service income	-	_*	-	(2)
Management fee income	-	_	-	(315)
Payment made on behalf		_	_	(28)
Affiliated company				
Management fee income	(9)	(9)	(19)	(19)
Rental income	(2)	(2)	(5)	(5)
Payment made on behalf	_	(2)	-	(2)

* Less than \$1,000

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2022

21 Comparatives

Certain amounts in the financial statements for the financial year ended 31 March 2021 have been reclassified to conform to current year's presentation for the following reasons:

- Operating subvention grants provided by the Government to the Group for purposes of providing subsidised nursing home care services to eligible patients who meet means test criteria are reclassified to revenue.
- Rental subvention grants for the purpose of defraying rental costs are reclassified to other income.

Effects of the prior year reclassifications above are shown below:

Income statement	Previously reported \$'000	Reclassifications \$'000	Balance as reported \$'000
Six months ended 31 March 2021			
Revenue	10,144	8,938	19,082
Operating subvention grants	9,125	(9,125)	_
Other income	3,106	187	3,293
Full year ended 31 March 2021			
Revenue	20,378	17,282	37,660
Operating subvention grants	17,531	(17,531)	_
Other income	6,219	249	6,468

22 Subsequent events

There are no known subsequent events which have led to adjustments to this set of condensed consolidated financial statements.

Other information required by Listing Rule Appendix 7.2

1 Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice.

The condensed consolidated statement of financial position of the Group as at 31 March 2022 and the related consolidated profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year ended 31 March 2022 and selected explanatory notes have not been audited or reviewed by our auditors.

2 Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of matter)

Not applicable.

3 Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:-

(a) Updates on the efforts taken to resolve each outstanding audit issue.

(b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

This is not required for any audit issue that is a material uncertainty relating to going concern.

Not applicable.

4 A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. The review must discuss any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors. It must also discuss any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on

(A) Statement of comprehensive income

FY2022 vs FY2021

Revenue

Revenue increased 3.3% or S\$1.2 million, from S\$37.7 million to S\$38.9 million. This was due to an increase in revenue of S\$1.5 million for Medicare centres and nursing home fees, which was offset by a decrease in ancillary fees of S\$0.3 million.

The increase in revenue for Medicare centres and nursing home fees was attributable to (i) increase of S\$0.3 million from China due to commencement of operations of ECON Medicare Centre and Nursing Home – Chongqing in May 2021, (ii) increase of S\$1.6 million from Singapore as a result of net increase in bed occupancy of 11, fee adjustment and the improvement in our homecare business (iii) commencement of operations for ECON Medicare Centre and Nursing Home – Puchong in December 2020, contributing additional S\$1.0 million revenue to Malaysia. These increases were partially offset by S\$1.4 million

Other information required by Listing Rule Appendix 7.2

decrease from ECON Medicare Centre and Nursing Home – Pudu as a result of the closure of the home.

Overall, our monthly average bed occupancy was 1,117 beds in FY2021 and 1,037 beds in FY2022. The total bed capacity was 1,376 and 1,231 for FY2021 and FY2022 respectively. Hence, the overall occupancy rate had increase from 81.2% in FY2021 to 84.2% in FY2022. The bed occupancy of ECON Medicare Centre and Nursing Home – Pudu for FY2021 was 150 out of 189 bed capacity. The closure of ECON Medicare Centre and Nursing Home – Pudu had been fully completed as at 31 March 2022.

Ancillary fees decreased by S\$0.3 million from S\$1.1 million to S\$0.8 million mainly due to the cessation of management fees charged to our related corporation, West Point Hospital Pte. Ltd, which owned and operated West Point Hospital, following the cessation of operation of West Point Hospital in August 2020.

Other income

Other income decrease by S\$1.3 million from S\$6.5 million in FY2021 to S\$5.2 million in FY2022. The decrease was mainly attributed to decrease in (i) the Job Support Scheme grants and foreign worker levy rebates of S\$1.8 million; (ii) the staff accommodation grants of S\$1.6 million, collectively the "Exceptional grant", as a result of COVID-19 pandemic. The decrease was partially offset by increase in new grants, such as S\$0.4 million of Job Growth Incentives grants, S\$0.4 million of Eldercare centre baseline service grants, S\$0.4 million of community Care Salary Enhancement grants, S\$0.2 million of rental support scheme, and S\$0.7 million of rental subvention grants. In addition, there was a S\$8,000 dividend income received from investment in quoted securities.

Supplies and consumables

Our cost of supplies and consumables increased by 7.1%, or S\$0.3 million, from S\$5.5 million in FY2021 to S\$5.8 million in FY2022. The increase was mainly due to the purchase of additional consumables for patients, such as food and milk feed, facemasks and dressing material, as revenue increase. There were also purchase of additional personal protective equipment, and disinfectants due to step up of the infection control & environmental hygiene practices due to the COVID-19 situation.

Staff costs

Our staff costs increased by 4.8% or S\$0.9 million from S\$18.5 million in FY2021 to S\$19.4 million in FY2022. This was mainly due to (i) increase in staffs costs of S\$0.9 million relating to salary enhancements, overtime payment and short-term contracted fee payment in Singapore, (ii) increase of S\$0.2 million of staff costs in China due to commencement of operations of the ECON Medicare Centre and Nursing Home – Chongqing as productivity has yet to reach the desirable stage as the private nursing homes take time to ramp up. These was offset by decrease in S\$0.3 million staff costs in Malaysia mainly due to the closure of the ECON Medicare Centre and Nursing Home – Pudu.

Other information required by Listing Rule Appendix 7.2

Depreciation of property, plant and equipment

Depreciation of property, plant and equipment increased by 22.8%, or S\$0.3 million, from S\$1.1 million in FY2021 to S\$1.4 million in FY2022 due to depreciation charge from the fixed assets for ECON Medicare Centre and Nursing Home – Puchong and ECON Medicare Centre and Nursing Home – Chongqing as they commenced operations in December 2020 and May 2021 respectively.

Depreciation of right-of-use assets

Depreciation of right-of-use assets increased by 16.2%, or S\$0.8 million, from S\$5.2 million in FY2021 to S\$6.0 million in FY2022 due to depreciation incurred for ECON Care Residences (Henderson) and ECON Medicare Centre and Nursing Home – Changshou.

Utilities expenses

Utilities expenses increased by S\$0.1 million from S\$0.9 million in FY2021 to S\$1.0 million in FY2022 mainly due to the increase in electricity tariff in Singapore.

Impairment losses on trade receivables

Impairment losses on trade receivables of S\$0.1 million mainly relates to impairment of uncollectible debts from ECON Medicare Centre and Nursing Home – Pudu following its closure.

Loss on investment in quoted securities, net

Net loss on investment in quoted securities amounted to S\$3.4 million mainly due to loss on disposal of Crosstec shares as announced on 12 January 2022.

Other operating expenses

Other operating expenses decreased by 2.2%, or S\$0.1 million, from S\$4.8 million in FY2021 to S\$4.7 million in FY2022. The decrease in other operating expenses was due to the absence in fees of S\$1.6m that the Group incurred for IPO project ("IPO Expense") in FY2021; offset by (i) increased in repair and maintenance expenses incurred of S\$0.6 million in relation to the upkeep for existing facilities, which was deferred last year due to lockdown; and (ii) increase in S\$0.5m expenses incurred for fixed assets written off, forfeiture of rental deposits, reinstatement costs for the closure of ECON Medicare Centre and Nursing Home – Pudu.

Finance costs, net

Net finance costs increased by 7.9%, or S\$0.1 million, from S\$1.4 million in FY2021 to S\$1.5 million in FY2022 due to the increase in lease liabilities.

Profit before tax

Profit before tax decreased by 87.4%, or S\$5.9 million, from S\$6.8 million in FY2021 to S\$0.9 million in FY2022. The decline in profit before tax was mainly brought about by the decrease in other income of S\$1.3 million which comprise mostly of grants, losses from the investment in quoted securities of S\$3.4 million and expenses incurred for the closure of ECON Medicare Centre and Nursing Home – Pudu of S\$0.5 million ("Pudu closure").

Other information required by Listing Rule Appendix 7.2

The normalised profit before tax is S\$4.1 million, a decrease of S\$0.9 million compared to S\$5.0 million in FY2021. The normalised profit is derived after excluding net Exceptional grants of S\$0.7 million, loss on investment in quoted securities, IPO Expense and Pudu closure.

Tax expense

Tax expense decreased by 37.0%, or S\$0.5 million, from S\$1.4 million in FY2021 to S\$0.9 million in FY2022 due to the decrease in profit before tax.

Profit attributable to owner of the company (PATMI)

As a result of the foregoing, our PATMI decreased by 93.9% or S\$5.3 million, from S\$5.7 million in FY2021 to S\$0.4 million in FY2022. PATMI margin decreased from 15.1% in FY2021 to 0.9% in FY2022.

Earnings per share (EPS) on a fully diluted basis for FY2022 was 0.14 cent compared to 2.75 cents for FY2021.

Net asset value (NAV) per share was 13.88 cents as at 31 March 2022 compared to 11.94 cents as at 31 March 2021 mainly due to higher share capital following the listing of the Company.

(B) Statement of financial position

Non-current assets

As at 31 March 2022, our non-current assets of S\$68.8 million accounted for 68.2% of our total assets. Our non-current assets comprised the following:

- (i) property, plant and equipment, which amounted to S\$17.9 million, and comprised freehold land and buildings, properties under construction, leasehold improvements and renovations, nursing homes and hospital equipment, ambulances and medical equipment, furniture, fittings and office equipment, computers and accessories and motor vehicles;
- (ii) right-of-use assets, which amounted to S\$40.9 million, and comprised nursing homes, office premise and health and wellness centres, office equipment, staff accommodation and motor vehicles;
- (iii) investment property, which amounted to S\$8.1 million, and is related to a freehold land that we own in Cheras, Malaysia. The land was leased to a third party lessee to operate an education centre;
- (iv) trade and other receivables, which amounted to S\$1.8 million, and is related to security deposits paid to our landlords and utilities providers;
- (v) deferred tax assets, which amounted to S\$0.1 million, in relation to lease accounting, provisions and tax loss carry-forwards; and
- (vi) investment in an associate amounting to \$\$53,000, of which the Group's interest is 20%.

The increase in non-current assets was mainly due to (i) increase in right-of-use assets of S\$13.7 million from the additions of lease contracts for ECON Care Residences (Henderson) and ECON Medicare Centre and Nursing Home – Changshou (ii) increase in property, plant and equipment for S\$1.5 million of the additions of construction-in-progress for ECON Medicare Centre and Nursing Home – Changshou and (iii) increase in trade and other receivables of S\$0.6 million due to security deposits paid to the landlord for ECON Care Residences (Henderson).

Other information required by Listing Rule Appendix 7.2

Current assets

As at 31 March 2022, our current assets of S\$31.9 million accounted for 31.7% of our total assets. Our current assets mainly comprised:

- (i) trade and other receivables, which amounted to \$\$5.6 million, comprising \$\$1.3 million of net third party trade receivables, \$\$2.6 million of government grant receivables, \$\$1.0 million of other receivables, \$\$0.4 million prepayments, and cumulatively accounted for 95.3% of total trade and other receivables;
- (ii) finance lease receivables, which amounted to S\$18,000;
- (iii) cash and cash equivalents, which amounted to S\$26.1 million or 81.5% of total current assets; and
- (iv) current tax assets, which amounted to S\$0.2 million.

The increase in current asset of S\$12.2 million was due to increase in cash and bank balances of S\$10.0 million and the increase in trade and other receivables of S\$2.2 million. The increase in trade and other receivables was mainly due to increase in government grant receivables for operating subvention grants of S\$0.4 million, other grant receivables of S\$1.2 million relating to rental subvention grants, grants on community care salary enhancements and healthcare hiring in advance initiatives, and other receivables of S\$0.9 million relating to the COVID-19 Healthcare Award provided by the Singapore government to recognise the contribution and dedication of healthcare staffs during the pandemic; offset by S\$0.3 million decrease in prepaid listing expenses.

Non-current liabilities

As at 31 March 2022, our non-current liabilities of S\$41.5 million accounted for 64.0% of our total liabilities. Our non-current liabilities mainly comprised:

- loans and borrowings, which amounted to S\$3.1 million, and is related to funding for the expansion of our Group's operations and general working capital purposes;
- (ii) deferred tax liabilities, which amounted to S\$0.4 million, and is related to differences arising from the recognition of depreciation expenses for our property, plant and equipment after the offsetting of tax losses carried forward;
- (iii) Deferred capital grants, which amounted to S\$1.6 million, and relating to government grants received for the purpose of equipping and furnishing the nursing homes.
- (iv) provision for restoration costs, which amounted to S\$0.6 million, and is related to the estimated costs of reinstating our leased premises to their original state upon termination or expiration of the leases; and
- (v) lease liabilities, which amounted to S\$35.7 million, being the non-current portion of the future lease payments.

The increase in non-current liabilities by 41.3% or S\$12.1 million, from S\$29.4 million to S\$41.5 million, which was due to the increase in the deferred capital grants of S\$1.3 million due to receipts of government grants relating to the upgrade to electric beds project for the nursing homes under the Healthcare Productivity Fund in Singapore and receipts of the renovation grants for ECON Medicare Centre and Nursing Home – Chongqing, increase in non-current lease liabilities of S\$12.1 million for the lease contracts for ECON Care Residences (Henderson) and ECON Medicare Centre and Nursing Home – Changshou; offset by a decrease in loan and borrowings of S\$1.4 million attributable to repayments of borrowings.

Other information required by Listing Rule Appendix 7.2

Current liabilities

As at 31 March 2022, our current liabilities of S\$23.3 million accounted for 36.0% of our total liabilities. Our current liabilities mainly comprised:

- (i) loans and borrowings, which amounted to S\$4.0 million, and is related to funding for the expansion of our Group's operations and general working capital purposes;
- (ii) trade and other payables, which amounted to S\$11.3 million, comprising S\$1.4 million of refundable deposits received from residents, S\$0.9 million of trade payables and S\$3.6 million of accrued operating expenses, S\$3.3 million of deferred grant income and cumulatively accounted for 82.1% of total trade and other payables;
- (iii) lease liabilities, which amounted to S\$7.1 million, being the present value of the future lease payments; and
- (iv) current tax liabilities, which amounted to S\$1.0 million.

The increase in current liabilities by 29.1% or S\$5.2 million, from S\$18.1 million as at 31 March 2021 to S\$23.3 million as at 31 March 2022. This was mainly due to increase in lease liabilities of S\$2.0 million due to additions of nursing home contracts for ECON Care Residences (Henderson) and ECON Medicare Centre and Nursing Home – Changshou, increase in trade and other payables of S\$5.3 million mainly due to increase in deferred grant income by S\$3.1 million relating to the receipt of pre-operations funding for ECON Care Residences (Henderson) to facilitate the ramp up of the nursing home operations, increase in accrued operating expenses of S\$2.1 million relating to staffs' bonuses, rental payments, and directors' fees.

(C) Statement of cash flows

Cash flow before changes in working capital for FY2022 amounted to S\$12.6 million. Net cash generated from operations was S\$13.8 million due to increase in trade and other receivables of S\$3.5 million and increase in trade and other payables of S\$4.7 million. As a result, net cash generated from operating activities after adjusting for cash paid for tax was S\$12.6 million.

Net cash flow used in investing activities was S\$4.5 million in FY2022. Net cash flows used were primarily for purchase of property, plant and equipment amounting to S\$2.6 million, investment in quoted securities of S\$5.1 million and capital injection of S\$83,000 for its 20% of interest in an associate. This was offset with capital grants received of S\$1.5 million and proceeds from disposal of quoted securities of S\$1.7 million.

Net cash flow from financing activities was S\$2.0 million in FY2022. This was attributable to the proceeds from shares issued pursuant to initial public offering of S\$14.0 million, and proceeds from bank borrowings of S\$0.1 million, capital contribution by non-controlling interests of S\$0.1 million. These increases were partially offset by the repayment of bank borrowings and lease liabilities of S\$3.3 million and S\$4.9 million respectively, dividends paid to shareholders of the Company of S\$2.6 million, interest paid of S\$1.1 million and payment of initial public offering transaction costs of S\$0.4 million.

Overall, the Group reported a net increase in cash and cash equivalents of S\$10.0 million for FY2022, ending the period with cash and cash equivalents of S\$26.1 million.

Other information required by Listing Rule Appendix 7.2

5 Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

Not applicable.

6 A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

With the COVID-19 situation easing in Singapore and Malaysia, the Group is cautiously optimistic that it can achieve organic growth especially with new nursing homes in its pipeline.

Operationally, the Group launched its ninth nursing home in Singapore, the 236-bed Econ Care Residence, Henderson ("ECON Henderson"), which soft-opened in April 2022. With 40 residents to date, ECON Henderson is housed within the first-ever integrated space for childcare, healthcare and urban farming at the former Henderson Secondary School building. The co-location of ECON Henderson in this integrated space will facilitate collaboration opportunities for inter-generational and therapeutic programmes with its partners, contributing towards quality of care for seniors.

The Group remains keen to prudently explore suitable expansion opportunities both in its existing markets as well as in other new markets.

7 Dividend

(a) Whether an interim (final) ordinary dividend has been declared (recommend); and

There is no final dividend declared or recommended for FY2022. The Company had declared an interim dividend of S\$0.22 cents per ordinary share for FY2022 and declared final dividend of S\$0.78 cents per ordinary share for FY2021.

(b)(i) Amount per share (in cents)

	FY2022 \$'000
Ordinary shares (tax exempt 1-tier) - Interim (0.22 Singapore cent per share) - Final	565
Total annual dividend	565

(b)(ii) Amount per share (in cents) for the previous corresponding period

The Company had declared a final dividend of S\$0.78 cents per ordinary share for FY2021.

Other information required by Listing Rule Appendix 7.2

(c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated).

Tax exempt one-tier.

(d) The date the dividend is payable

Not applicable

(e) The date on which Registrable Transfers received by the company (up to 5.00 pm) will be registered before entitlements to the dividend are determined

Not applicable

(f) If no dividend has been declared (recommended), a statement to that effect and the reason(s) for the decision.

No final dividend is declared or recommended as the Group had reported a significantly lower profit for FY2022. The Group plans to conserve cash for exploring further expansion of the Group.

8 Breakdown of revenue and profit after tax

	Group		
	FY2022	FY2021	Change (%)
(a) Sales reported for first half year	19,580	18,578	5.4
(b) Operating profit after tax before deducting minority interests reported for first half year	1,421	3,537	(59.8)
(c) Sales reported for second half year	19,325	19,082	1.3
(d) Operating (loss)/profit after tax before deducting minority interests reported for second half year	(1,477)	1,834	(180.5)

Other information required by Listing Rule Appendix 7.2

9 If the Group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

Name of Interested Person	Aggregate value (\$'000) of all IPTs during the financial period under review	Aggregate value of all IPTs conducted during the financial year under review under shareholders' mandate pursuant to Rule 920 (excluding transactions less than S\$100,000)
 (1) Econ Healthcare Pte Ltd Lease of 3 nursing homes: (a) ECON Medicare Centre and Nursing Home – Braddell (b) ECON Medicare Centre and Nursing Home – Choa Chu Kang (c) ECON Medicare Centre and Nursing Home – Upper East Coast (2) Econ Medicare Centre Holdings Pte Ltd (a) Lease of ECON Medicare Centre and Nursing Home – Recreation Road (b) Lease of staff quarters at Recreation Road 	1,532	Not applicable - the Group does not have a shareholders' mandate under Rule 920 for Interested Person Transactions
 (c) Sublease agreement for Hexacube office (d) Accounting service agreement (3) Econ Healthcare Pte Ltd (a) Sub lease agreement for Chai Chee Nursing Home 	704	
(4) Ekang International Holdings Pte. Ltd.(a) Lease of Hexacube office	488	
 (5) TMI Technologies Pte Ltd (a) Sub lease arrangement for Hexacube office (b) Accounting service agreement 	12	

10 Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7.7) under Rule 720(1).

The Company has procured undertakings from all its Directors and Executive Officers (in the format set out in Appendix 7H) under Rule 720(1) of the Catalist Rules.

Other information required by Listing Rule Appendix 7.2

11 Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(13) in the format below. If there are no such persons, the issuer must make an appropriate negative statement.

Name	Age	Family relationship with any director, CEO and/or substantial shareholder	Current position and duties, and the year the position was first held	Details of changes in duties and position held, if any, during the year
Koh Hin Ling	68	Wife of Ong Chu Poh (Executive Chairman and Group Chief Executive Officer); and Mother of Ong Hui Ming (Executive Director and Deputy Chief Executive Officer)	Director of TCM, TCM practitioner and Director of the Group's principal subsidiaries, with effect from 1994	N.A.
Ong Xin De	38	Son of Ong Chu Poh (Executive Chairman and Group Chief Executive Officer); and Brother of Ong Hui Ming (Executive Director and Deputy Chief Executive Officer)	Head, Development, with effect from 2017, overseeing strategic development, growth, technology and innovation of the Group	N.A.

Other information required by Listing Rule Appendix 7.2

12 Use of IPO proceeds

Pursuant to the initial public offering on 19 April 2021, the Company received gross proceeds of S\$14.0 million from the placement of new shares. As at the date of this announcement, the IPO net proceeds have been utilised as follows:

	Amount allocated (as disclosed in the offer document) \$'000	Amount utilised as at the date of this announcement \$'000	Balance \$'000
Expansion plans in Singapore as well as overseas through, among others, joint ventures, strategic collaborations, mergers and acquisitions, or investments Upgrading of existing medicare centres and	7,500	1,228	6,272
nursing homes and other facilities, including equipment and IT infrastructure General corporate and working capital	2,000	60	1,940
purposes Payment of underwriting and placement	2,000	_	2,000
commissions and offering expenses ("IPO expenses") Total	<u>2,500</u> 14,000	2,430 ⁽¹⁾ 3,718	70 10,282

⁽¹⁾ The amount utilised as at the date of this announcement refer to the expenses billed to date and amount paid up to date.

BY ORDER OF THE BOARD

Ong Chu Poh Executive Chairman and Group Chief Executive Officer 27 May 2022